Heparin and low-molecular-weight heparin : Current use of biologicals in thrombosis and haemostasisGRAY, Elaine; MULLOY, Barbara; BARROWCLIFFE, Trevor W et al.Thrombosis and haemostasis. 2008, Vol 99, Num 5, pp 807-818, issn 0340-6245, 12 p.Article

Heparin to pentasaccharide and beyond: The end is not in sightMESSMORE, Harry L; WEHRMACHER, William H; COYNE, Erwin et al.Seminars in thrombosis and hemostasis. 2004, Vol 30, pp 81-88, issn 0094-6176, 8 p., SUP1Conference Paper

Differentiating Low-Molecular-Weight Heparins Based on Chemical, Biological, and Pharmacologic Properties : Implications for the Development of Generic Versions of Low-Molecular-Weight HeparinsJESKE, Walter P; WALENGA, Jeanine M; HOPPENSTEADT, Debra A et al.Seminars in thrombosis and hemostasis. 2008, Vol 34, Num 1, pp 74-85, issn 0094-6176, 12 p.Article

The effect of taurolidine on experimental thrombus formationKAPTANOGLU, Levent; KUCUK, Hasan Fehmi; COLAK, Elif et al.European journal of pharmacology. 2008, Vol 578, Num 2-3, pp 238-241, issn 0014-2999, 4 p.Article

Extending the role of antithrombotic agents: An example based on the low-molecular-weight heparin, tinzaparinHAINER, James W; SPROGEL, Per; LINDENSTROEM, Ewa et al.Seminars in thrombosis and hemostasis. 2004, Vol 30, pp 3-9, issn 0094-6176, 7 p., SUP1Conference Paper

Low-molecular-weight heparin in pediatric patientsSUTOR, Anton Heinz; CHAN, Anthony K. C; MASSICOTTE, Patricia et al.Seminars in thrombosis and hemostasis. 2004, Vol 30, pp 31-39, issn 0094-6176, 9 p., SUP1Conference Paper

Hospital guidelines for use of low-molecular-weight heparinsNUTESCU, Edith A; LEWIS, Richard K; FINLEY, Jamie M et al.The Annals of pharmacotherapy. 2003, Vol 37, Num 7-8, pp 1072-1081, issn 1060-0280, 10 p.Article

Timing of postpartum enoxaparin administration and severe postpartum hemorrhageFREEDMAN, Rachel A; BAUER, Kenneth A; NEUBERG, Donna S et al.Blood coagulation & fibrinolysis. 2008, Vol 19, Num 1, pp 55-59, issn 0957-5235, 5 p.Article

Differential effects of heparin and low molecular weight heparin on osteoblastogenesis and adipogenesis in vitroOSIP, Stephanie L; BUTCHER, Martin; YOUNG, Edward et al.Thrombosis and haemostasis. 2004, Vol 92, Num 4, pp 803-810, issn 0340-6245, 8 p.Article

Structural features of low-molecular-weight heparins affecting their affinity to antithrombinBISIO, Antonella; VECCHIETTI, Davide; CITTERIO, Laura et al.Thrombosis and haemostasis. 2009, Vol 102, Num 5, pp 865-873, issn 0340-6245, 9 p.Conference Paper

Low molecular weight heparin in pregnancy: current issuesGREER, Ian; HUNT, Beverley J.British journal of haematology. 2005, Vol 128, Num 5, pp 593-601, issn 0007-1048, 9 p.Article

The potential for circular dichroism as an additional facile and sensitive method of monitoring low-molecular-weight heparins and heparinoidsRUDD, Timothy R; SKIDMORE, Mark A; GUIMOND, Scott E et al.Thrombosis and haemostasis. 2009, Vol 102, Num 5, pp 874-878, issn 0340-6245, 5 p.Conference Paper

Guidelines on the use and monitoring of heparinBAGLIN, T; BARROWCLIFFE, T. W; COHEN, A et al.British journal of haematology. 2006, Vol 133, Num 1, pp 19-34, issn 0007-1048, 16 p.Article

A common standard is inappropriate for determining the potency of ultra low molecular weight heparins such as semuloparin and bemiparinJESKE, Walter P; HOPPENSTEADT, Debra; GRAY, Angel et al.Thrombosis research. 2011, Vol 128, Num 4, pp 361-367, issn 0049-3848, 7 p.Article

Long-Term Use of Low-Molecular-Weight Heparin in Hemodialysis Patients : A 7-Year ExperienceBERNIEH, B; BOOBES, Y; AL HAKIM, M. R et al.Blood purification. 2009, Vol 27, Num 3, pp 242-245, issn 0253-5068, 4 p.Article

Generic low-molecular-weight heparins: Some practical considerationsFAREED, Jawed; LEONG, Wendy L; HOPPENSTEADT, Debra A et al.Seminars in thrombosis and hemostasis. 2004, Vol 30, Num 6, pp 703-713, issn 0094-6176, 11 p.Conference Paper

Development of generic low molecular weight heparins: A perspectiveFAREED, Jawed; LEONG, Wendy; HOPPENSTEADT, Debra A et al.Hematology/oncology clinics of North America. 2005, Vol 19, Num 1, pp v-vi, issn 0889-8588, 18 p.Article

Clinical Differentiation of Low Molecular Weight HeparinsMAMMEN, Eberhard F; ARCELUS, Juan; MESSMORE, Harry et al.Seminars in thrombosis and hemostasis. 2008, Vol 34, Num 8, issn 0094-6176, A45-A55Article

Attention à l'administration itérative d'HBPM au voyageurLECOMPTE, Thomas.Archives des maladies du coeur et des vaisseaux. Pratique. 2005, Num 136, issn 1261-694X, p. 10Article

Low molecular weight heparin in childrenALBISETTI, Manuela; ANDREW, Maureen.European journal of pediatrics. 2002, Vol 161, Num 2, pp 71-77, issn 0340-6199Article

Pharmacodynamic considerations in the selection of dosage of tinzaparin for various indications: Experimental studies in primatesJESKE, Walter; FAREED, Jawed.Seminars in thrombosis and hemostasis. 2004, Vol 30, pp 41-47, issn 0094-6176, 7 p., SUP1Conference Paper

Venous thromboembolic prophylaxis in hospitalized medical patientsSTARK, Jennifer E; KILZER, Wanda J.The Annals of pharmacotherapy. 2004, Vol 38, Num 1, pp 36-40, issn 1060-0280, 5 p.Article

Tissue factor and fibrin in tumor angiogenesisFERNANDEZ, Patricia M; PATIERNO, Steven R; RICKLES, Frederick R et al.Seminars in thrombosis and hemostasis. 2004, Vol 30, Num 1, pp 31-44, issn 0094-6176, 14 p.Article

Low-molecular-weight heparin pharmacokinetics: a dual absorption model approachABE, Sadahiro; CHIBA, Koji; SUWA, Toshio et al.International journal of clinical pharmacology and therapeutics. 2013, Vol 51, Num 6, pp 482-489, issn 0946-1965, 8 p.Article

Outcomes in women receiving low-molecular-weight heparin during pregnancyDE SANCHO, Maria T; KHALID, Sana; CHRISTOS, Paul J et al.Blood coagulation & fibrinolysis. 2012, Vol 23, Num 8, pp 751-755, issn 0957-5235, 5 p.Article